Clincosm LogoSign in Get a demo

Recurrent Ovarian Carcinoma

Showing NaN - NaN of 15
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +14 more
  • Birmingham, Alabama
  • +399 more
Dec 30, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

Active, not recruiting
  • COL6A3 Positive
  • +3 more
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma Trial in Houston (Computed Tomography, Fludeoxyglucose F-18,

Recruiting
  • Breast Carcinoma
  • +7 more
  • Computed Tomography
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 24, 2022

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)

Recruiting
  • Bone Sarcoma
  • +15 more
  • Aldesleukin
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston

Recruiting
  • Malignant Female Reproductive System Neoplasm
  • +24 more
  • Quality-of-Life Assessment
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 6, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma

Completed
Has Results
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +17 more
  • Phoenix, Arizona
  • +162 more
Sep 28, 2021

Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Carcinoma Trial in Korea, Republic of, United States (Laboratory Biomarker

Completed
Has Results
  • Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Carcinoma
  • Laboratory Biomarker Analysis
  • Sunitinib Malate
  • Birmingham, Alabama
  • +96 more
Feb 6, 2020

Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma Trial in Canada,

Completed
Has Results
  • Adult Hepatocellular Carcinoma
  • +44 more
  • Scottsdale, Arizona
  • +60 more
Jan 24, 2019

Collecting Tumor Samples From Patients With Gynecological Tumors

Completed
  • Borderline Ovarian Clear Cell Tumor
  • +85 more
  • Laboratory Biomarker Analysis
  • Fayetteville, Arkansas
  • +186 more
Oct 26, 2016

Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States (Akt Inhibitor MK2206,

Completed
Has Results
  • Ovarian Sarcoma
  • +3 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +5 more
May 16, 2016